Compositions and methods of treating muscular dystrophy with thromboxane-A
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist.
1. A method of treating Duchenne muscular dystrophy in a patient in need of treatment thereof, comprising administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to the patient, wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , further comprising administering the thromboxane A 2 antagonist to the patient on a chronic basis.
3. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
4. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally.
5. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered parenterally.
6. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally.
7. The method of claim 2 , wherein the thromboxane A 2 receptor antagonist is administered prophylactically to prevent cardiomyopathy in the patient.
8. The method of claim 2 , wherein the thromboxane A 2 receptor antagonist is administered prophylactically to prevent gastrointestinal dysfunction in the patient.
9. The method of claim 1 , wherein the therapeutically effective amount is from 50 mg to 500 mg per day.
10. The method of claim 1 , wherein the therapeutically effective amount is from 150 mg to 350 mg per day and the ifetroban or pharmaceutically acceptable salt thereof is administered orally.
11. A method of treating cardiac dysfunction in a human patient suffering from muscular dystrophy, comprising administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to the human patient, wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the therapeutically effective amount is from 50 mg to 500 mg per day.
13. The method of claim 11 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
14. The method of claim 11 , wherein the therapeutically effective amount is from 150 mg to 350 mg per day and the ifetroban or pharmaceutically acceptable salt thereof is administered orally.
15. The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally once per day.
16. The method of claim 15 , wherein the therapeutically effective amount is 50 mg.
17. The method of claim 15 , wherein the therapeutically effective amount is 100 mg.
18. The method of claim 15 , wherein the therapeutically effective amount is 150 mg.
19. The method of claim 15 , wherein the therapeutically effective amount is 300 mg.
20. The method of claim 11 , wherein the thromboxane A 2 receptor antagonist is administered orally once per day.